MedPath

Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection

Not Applicable
Conditions
Lung Function Decreased
Tracheal Intubation Morbidity
Non-small Cell Lung Cancer
Interventions
Procedure: Nonintubated thoracoscopic lobectomy
Procedure: Intubated thoracoscopic lobectomy
Registration Number
NCT03471884
Lead Sponsor
National Taiwan University Hospital
Brief Summary

A novel nonintubated thoracoscopic technique is promising to enhance recovery after thoracic surgery. However, the effects of nonintubated technique on specific organ protection in not clear yet. In this randomized trial, the effect of nonintubated technique on lung function protection will be evaluated via PaO2/FiO2 ratio, oxidative stress and inflammatory cytokines serially in lung cancer patients undergoing thoracoscopic lobectomy.

Detailed Description

Lung cancer is the leading cause of cancer-related death worldwide. Its incidence is increasingly arising recently. For early-stage non-small cell lung cancer, surgery is the standard treatment that offers best chance of survival. For thoracoscopic lung cancer surgery, tracheal intubation with one-lung ventilation is regarded the standard anesthetic management to establish a safe operating environment. However, complications associated with intubated general anesthesia are not negligible. A novel nonintubated thoracoscopic technique is developing and applied in a variety of thoracic diseases. A previous study showed that nonintubated thoracoscopic lobectomy was feasible and safe in lung cancer patients. Furthermore, nonintubated techniques was also associated with a faster recovery of oral intake, less postoperative complications and shorter hospital stay. The effects of nonintubated thoracoscopic technique on specific organ protection is not clear yet.

The aim of this investigation is to explore the effects of nonintubated thoracoscopic lobectomy on lung function protection in lung cancer patients, comparing with the standard intubated patients as a control. The investigators are going to enrol 82 lung cancer patients and randomize them equally to complete thoracoscopic lobectomy with lymphadenectomy either with a nonintubated technique (n=41) or an intubated technique (n=41). The assessment of lung function will be obtained from serial blood gas analyses using PaO2/FiO2 ratio. Additionally, oxidative stress and inflammatory cytokines will be measured from serial blood samples including 8-isoprostane, malondialdehyde, tumor necrosis factor-α, interleukin-6, interleukin-10, S100-β and neuron specific enolase.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
82
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nonintubated thoracoscopic lobectomyNonintubated thoracoscopic lobectomyLung cancer patients undergoing thoracoscopic lobectomy without tracheal intubation
Intubated thoracoscopic lobectomyIntubated thoracoscopic lobectomyLung cancer patients undergoing thoracoscopic lobectomy with tracheal intubation and one-lung ventilation
Primary Outcome Measures
NameTimeMethod
Lung function assessment12 hours

Lung function will be assessed by serial arterial blood gas analyses to obtain oxygenation index (PaO2/FiO2).

Secondary Outcome Measures
NameTimeMethod
Oxidative and systemic inflammatory cytokines.24 hours

Oxidative and systemic inflammatory cytokines will be measured from serial blood samples, including 8-isoprostane (pg/mL), malondialdehyde (nM), tumor necrosis factor-alpha (pg/mL), interleukin-6 (pg/mL), interleukin-10 (pg/mL), S100-beta (pg/mL), and neuron specific enolase (ng/mL).

Trial Locations

Locations (1)

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath